I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $38.6M
Company Location Date Amt. (M) Investors
Acorda Therapeutics Hawthorne, 10/15 $20 Acorda placed 7.47M shares of Series E preferred
Inc. (3rd round) N.Y. stock with a group of institutional investors led by
BB Bioventure Fund and Vector Fund Management; also
participating were MSC Capital Corp. and New York Life
Del Mar Medical San Diego 10/22 $3.3 Investors in this round included Kleiner, Perkins, Caufield
Technologies Inc. and Byers and Technology Partners
(1st round)
FeRx Inc. San Diego 10/12 $7.3 FeRx received $7.25M in venture capital financing,
(2nd round) including $3.5M from Brentwood Venture Capital; the
remainder was raised from private investors
Osiris Therapeutics Baltimore 10/1 $8 Osiris received $8M in guaranteed financing from Alex-
Inc. (other) andria Real Estate Equities Inc.; Alexandria bought
Osiris' research labs and pilot GMP stem cell production
facilities from 3rd parties and guaranteed $8M to Osiris
for future lab and stem cell production improvements
II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM CORPORATE PARTNERS: $13.0M
Company Partner Amt. Triggering Details (Date)
(Symbol) (Symbol; Country) (M) Event
Atrix Laboratories Block Drug Corp. $5 First product The companies entered an agreement in 12/96
Inc. (ATRX) (NASDAQ:BLOCA) shipment for Block Drug to market Atridox for treating
periodontal disease in North America; Block
began the 1st shipment of product to dentists,
triggering the $5M milestone payment (10/9)
The Immune Agouron Pharma- $5 Quarterly The companies entered an agreement in 6/98 to
Response Corp. ceuticals Inc. (AGPH) payment collaborate on the final development and com-
(IMNR) mercialization of the immune-based therapy
Remune for treating HIV infection; this is the
1st in a series of quarterly payments Agouron
will make to Immune Response; it consists of
$3M for R&D and $2M for the purchase of 0.13M
shares of unregistered common stock (10/19)
Transkaryotic Hoechst Marion $2.5 Hoechst The companies signed an agreement in 1994 to
Therapies Inc. Roussel Inc. (unit Marion develop gene-activated drugs; Hoechst Marion
(TKTX) of Hoechst AG; initiated initiated Phase III trials of GA-EPO (erythro-
Germany) Phase III trial poietin), triggering the $2.5M milestone (9/29)*
of GA-EPO
Vertex Pharma- Glaxo Wellcome plc $3 Glaxo sub- The companies signed a collaboration to develop
ceuticals Inc. (VRTX) (NYSE:GLX; U.K.) mitted NDA HIV protease inhibitors in 12/93; Glaxo submit-
on Agenerase ted an NDA to FDA on Vertex's drug Agenerase
(amprenavir), triggering a $3M milestone pay-
ment to Vertex (10/16)
NOTE:
* Transkaryotic Therapies Inc. received its milestone payment in 9/98. The sum has been attributed to that month and is not included in the totals listed above.
III. PIPE/REG. S FINANCINGS: $0M
There were no PIPE/Reg. S financings in October.

No Comments